Chairman and CEO, Peplin Inc
| Role | Organisation | Sources |
|---|---|---|
| Chairman and CEO | Peplin Inc | GBS Ventures (3 Sep 2009), GBS Ventures (19 May 2009), GBS Ventures (18 Aug 2008) |
| Chief Executive Officer | Peplin, Inc. | GBS Ventures (23 Jul 2009), GBS Ventures (8 Jan 2009), GBS Ventures (16 Dec 2008), GBS Ventures (18 Aug 2008) |
Stories naming Tom Wiggans. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
LEO Pharma has struck a deal to buy ASX-listed Peplin for roughly US$287.5 million, with its two biggest shareholders, including GBS Venture Partners, backing the transaction.
Also GBS Ventures
Peplin has begun a second Phase 3 trial of its skin-lesion gel, seeking to confirm earlier clearance results at non-head sites, with a regulatory filing planned for mid-2010.
A Brisbane skin-cancer biotech reports successful late-stage results for its sun-spot gel, saying it remains on schedule for a US regulatory filing and a 2011 market launch.
Peplin reports its PEP005 gel met the primary endpoint in a Phase IIb actinic keratosis trial, clearing lesions safely across doses and moving toward Phase III development.
ASX-listed biotech Peplin has finished enrolling 250 patients in the first Phase III trial of its PEP005 Gel treatment for actinic keratosis, with results expected in H1 2009.
ASX-listed biotech Peplin arranged a private placement of roughly US$24 million to advance its keratosis drug into Phase III testing, led by GBS Venture Partners with several existing shareholders also taking part.
Peplin hires Tom Wiggans as CEO and Eugene Bauer as President/CMO while Michael Aldridge steps down; the dermatology company also announces a US$24m capital raising and a merger agreement with Neosil.